Misako Nagasaka

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 55

Top Topics

Squamous Cell Carcinoma

African American

Small Cell Lung Cancer

Top Venues

Lung Cancer (Auckland, N.Z.)

Targeted oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Danielle Brazel, Misako Nagasaka
The APPLE trial in the evolving landscape of ctDNA monitoring. Translational lung cancer research 13 (6) (2024)
Danielle Brazel, Misako Nagasaka
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckland, N.Z.) 15 (2024)
Zhaohui Liao Arter, Misako Nagasaka
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckland, N.Z.) 15 (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Misako Nagasaka
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Targeted oncology 19 (3) (2024)
Danielle Brazel, Misako Nagasaka
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Targeted oncology 19 (3) (2024)
Danielle Brazel, Misako Nagasaka
The APPLE trial in the evolving landscape of ctDNA monitoring. Translational lung cancer research 13 (6) (2024)
Danielle Brazel, Misako Nagasaka
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Misako Nagasaka
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Targeted oncology (2024)
Zhaohui Liao Arter, Misako Nagasaka
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Misako Nagasaka
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckland, N.Z.) 15 (2024)
Dalia Kaakour, Misako Nagasaka
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions. Lung Cancer (Auckland, N.Z.) 15 (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Dan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, Estelamari Rodriguez, Harris B Krause, Jennifer R Ribeiro, Heng Tan, Emmanuel S Antonarakis, Emil Lou, Misako Nagasaka, Sandra Algaze, Heinz-Josef Lenz, Stephen V Liu, Balazs Halmos, Dave S B Hoon, Peter Andreas Seeber, Patrick C Ma, Wafik S El-Deiry, Ari M VanderWalde, Gilberto de Lima Lopes
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The oncologist (2024)
Danielle Brazel, Misako Nagasaka
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Targeted oncology 19 (3) (2024)
Zhaohui Liao Arter, Misako Nagasaka
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? Lung Cancer (Auckland, N.Z.) 15 (2024)
Zhaohui Liao Arter, Misako Nagasaka
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Misako Nagasaka
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Targeted oncology 19 (3) (2024)
Zhaohui Liao Arter, Misako Nagasaka
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK -Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Misako Nagasaka
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckland, N.Z.) 14 (2023)
Jeffrey Ahn, Misako Nagasaka
Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations. Cancer management and research 15 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckland, N.Z.) 14 (2023)
Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, Osama Alkhalili, Mohammed H Uddin, Sahar F Bannoura, Yousef Mzannar, Ibrahim Hanna Azar, Eliza Wright Beal, Miguel Tobon, Steve H Kim, Rafic Beydoun, Erkan Baloglu, William Senapedis, Bassel F El-Rayes, Philip A Philip, Ramzi M Mohammad, Anthony Frank Shields, Mohammad Najeeb Al-Hallak, Asfar S Azmi
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. Molecular cancer therapeutics (2023)
Shannon S Zhang, Alexandria T M Lee, Misako Nagasaka
CodeBreak 200: Sotorasib Has Not Broken the KRAS G12C Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Misako Nagasaka
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckland, N.Z.) 14 (2023)
Misako Nagasaka, Sai-Hong Ignatius Ou
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckland, N.Z.) 14 (2023)
Shannon S Zhang, Alexandria T M Lee, Misako Nagasaka
CodeBreak 200: Sotorasib Has Not Broken the KRAS G12C Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Robert C Hsu, David J Benjamin, Misako Nagasaka
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review. Cancers 15 (14) (2023)
Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, Osama Alkhalili, Mohammed H Uddin, Sahar Bannoura, Yousef Mzannar, Ibrahim Azar, Eliza Beal, Miguel Tobon, Steve Kim, Rafic Beydoun, Erkan Baloglu, William Senapedis, Bassel El-Rayes, Philip A Philip, Ramzi M Mohammad, Anthony F Shields, Mohammed Najeeb Al-Hallak, Asfar S Azmi
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. bioRxiv : the preprint server for biology (2023)
Misako Nagasaka, Sai-Hong Ignatius Ou
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckland, N.Z.) 14 (2023)
Yusra F Shao, Seongho Kim, John D Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho-Sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer. Head & neck 44 (10) (2022)
David J Benjamin, Misako Nagasaka
Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Misako Nagasaka, Cliff Molife, Zhanglin Lin Cui, Victoria Stefaniak, Xiaohong Li, Sangmi Kim, Hsui-Yung Lee, Julia Beyrer, George Blumenschein
Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer. Future oncology (London, England) 18 (16) (2022)
Hui Wang, Zhi-Wei Li, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Sai-Hong Ignatius Ou, Yu Yang
NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer medicine 11 (13) (2022)
Ziad Abuhelwa, Abdurahman Alloghbi, Ali Alqahtani, Misako Nagasaka
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. Drugs 82 (9) (2022)
Danielle Brazel, Gianna Kroening, Misako Nagasaka
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 36 (6) (2022)
Misako Nagasaka, Asfar S Azmi
Clinical progress of KRAS-targeted therapies: what next? Future medicinal chemistry 14 (15) (2022)
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako Nagasaka, Javier García Corbacho, Shadia Jalal, James J Harding, Stella K Kim, Iris H C Miedema, Danielle J Vugts, Marc C Huisman, Gerben J C Zwezerijnen, Guus A M S van Dongen, Catharina Willemien Menke-van der Houven van Oordt, Song Wang, Tam Dang, Ivan A Zein, Olga Vasiljeva, Susan K Lyman, Virginia Paton, Alison Hannah, Joyce F Liu
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (10) (2022)
Danielle Brazel, Misako Nagasaka
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC. Lung Cancer (Auckland, N.Z.) 13 (2022)
Danielle Brazel, Shannon S Zhang, Misako Nagasaka
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer (Auckland, N.Z.) 13 (2022)
Danielle Brazel, Zhaohui Arter, Misako Nagasaka
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. Lung Cancer (Auckland, N.Z.) 13 (2022)
Jennifer L Leddon, Shuchi Gulati, Sulsal Haque, Casey Allen, Sarah Palackdharry, Maria Mathews, Nicky Kurtzweil, Muhammed Kashif Riaz, Vinita Takiar, Misako Nagasaka, Yash Patil, Chad Zender, Alice Tang, Brian Cervenka, Julie McGrath, Wolfgang Michael Korn, Benjamin H Hinrichs, Roman Jandarov, Nusrat Harun, Ammar Sukari, Trisha Michel Wise-Draper
Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)
Misako Nagasaka, Sai-Hong Ignatius Ou
ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression? Lung Cancer (Auckland, N.Z.) 13 (2022)
Misako Nagasaka, Mohammed Hafiz Uddin, Mohammed Najeeb Al-Hallak, Sarah Rahman, Suresh Balasubramanian, Ammar Sukari, Asfar S Azmi
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular cancer 20 (1) (2021)
Daniel L Quan, Ammar Sukari, Misako Nagasaka, Harold Kim, John D Cramer
Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head & neck 43 (11) (2021)
Shannon S Zhang, Misako Nagasaka
Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 12 (2021)
Ibrahim Hanna Azar, Samer Alkassis, Jami Fukui, Fares Alsawah, Kalub Fedak, Mohammed Najeeb Al Hallak, Ammar Sukari, Misako Nagasaka
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 12 (2021)
Danielle Brazel, Misako Nagasaka
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 12 (2021)
Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca, Joanne Xiu, Ari M VanderWalde, Hirva Mamdani, Luis E Raez, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A Socinski, Jorge J Nieva, Chul Kim, Antoinette J Wozniak, Chukwuemeka Ikpeazu, Gilberto de Lima Lopes, Alexander I Spira, Wolfgang Michael Korn, Edward S Kim, Stephen V Liu, Hossein Borghaei
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Molecular cancer therapeutics 20 (12) (2021)
Alexander E Drilon, Michael Duruisseaux, Ji-Youn Han, Masaoki Ito, Christina J Falcon, Soo-Ryum Yang, Yonina R Murciano-Goroff, Haiquan Chen, Morihito Okada, Miguel Ángel Molina-Vila, Marie Wislez, Philippe Brun, Clarisse Dupont, Eva Branden, Giulio Rossi, Alexa B Schrock, Siraj M Ali, Valérie Gounant, Fanny Magne, Torsten Gerriet Blum, Alison M Schram, Isabelle Monnet, Jin-Yuan Shih, Joshua K Sabari, Maurice Pérol, Viola W Zhu, Misako Nagasaka, Robert Doebele, D Ross Camidge, Maria Arcila, Sai-Hong Ignatius Ou, Denis Moro-Sibilot, Rafael Rosell, Lucia Anna Muscarella, Stephen V Liu, Jacques Cadranel
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (25) (2021)
Viola W Zhu, Misako Nagasaka, Takafumi Kubota, Kunil Raval, Natasha Robinette, Octavio Armas, Wajd Al-Holou, Sai-Hong Ignatius Ou
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. Lung Cancer (Auckland, N.Z.) 11 (2020)
Ammar Sukari, Misako Nagasaka, Maria Diab, Khaled Al Sibai, Bassel Atassi, Jailan A Elayoubi, Seongho Kim, Ömer Küçük
Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 44 (4) (2019)
Misako Nagasaka, Nadine H Abdallah, Marcus Crosby, Nithin Thummala, Dhaval Patel, Antoinette J Wozniak, Shirish Gadgeel, Judith Abrams, Ammar Sukari
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Lung Cancer (Auckland, N.Z.) 10 (2019)
Misako Nagasaka, Nadine Abdallah, Julie Samantray, Ammar Sukari
Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. Clinical case reports 6 (7) (2018)